Twist Bioscience
TWST
193 hedge funds and large institutions have $1.39B invested in Twist Bioscience in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 72 increasing their positions, 46 reducing their positions, and 38 closing their positions.
58% more call options, than puts
Call options by funds: $7.3M | Put options by funds: $4.61M
57% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 46
46% more capital invested
Capital invested by funds: $957M → $1.39B (+$437M)
7.85% more ownership
Funds ownership: 111.42% → 119.27% (+7.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 201 → 193 (-8)
18% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 38
Top Buyers
| 1 |
Millennium Management
New York
|
+$37.1M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
+$23.4M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$22.1M |
| 4 |
JP Morgan Chase
New York
|
+$16.2M |
| 5 |
BlackRock
New York
|
+$10.4M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$35.1M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$12.4M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.94M |
| 4 |
State Street
Boston,
Massachusetts
|
-$6.42M |
| 5 |
Two Sigma Investments
New York
|
-$6.24M |
TWST Hedge Fund Activity: Q2 2023 in Review
193 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q2 2023, worth a combined $1.39B — up 46% from $957M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of TWST and 31 opened new positions — a net loss of 7 holders — while 46 trimmed existing stakes and 72 added.
The largest buyer was Millennium Management, adding an estimated $37.1M. The largest seller was Fidelity Investments, cutting an estimated $35.1M.
- 193 institutional investors held Twist Bioscience (TWST) as of Q2 2023, down from 201 in Q1 2023.
- Funds reported $1.39B of Twist Bioscience stock for Q2 2023, up 46% quarter-over-quarter.
- 31 funds opened new Twist Bioscience positions in Q2 2023 and 38 closed out, a net change of -7 holders.
- The largest Twist Bioscience buyer in Q2 2023 was Millennium Management, an estimated $37.1M added.
- The largest Twist Bioscience seller in Q2 2023 was Fidelity Investments, an estimated $35.1M sold.
Based on aggregated 13F filings for Q2 2023.